Target intelligence / Profile preview

PARK7 pseudogene 2 (PARK7P2)

Target
PARK7P2
Molecular classification
Other (pseudogene)
01

Overview

PARK7 pseudogene 2 (PARK7P2) is a non-protein-coding genomic sequence annotated as a pseudogene of PARK7 (DJ-1), which means it does not produce a functional protein. There is no evidence supporting a role for PARK7P2 in cellular function, disease, or therapeutic intervention. By contrast, the PARK7 (DJ-1) gene encodes a protein involved in oxidative stress response, neuroprotection, protein folding, and is genetically associated with hereditary forms of Parkinson's disease[3][2][1]. PARK7P2 is not referenced in the biomedical literature as a target for drug discovery or as relevant to disease biology, suggesting that it is not a molecular target of current scientific or clinical interest. If you seek information about PARK7 (DJ-1)—a canonical target implicated in neurodegenerative disorders—I can provide those details. For PARK7P2, current evidence suggests it is not a therapeutic, diagnostic, or biological target.

Other names
DJ-1 pseudogene 2
02

Mechanism of action

None (not a functional molecule for drug mechanism)

03

Biological functions

None established (pseudogenes typically do not encode functional proteins or have characterized biological roles)
04

Disease associations

None established (no known implication in disease; research focuses on PARK7, not PARK7P2)
05

Safety considerations

None (no therapeutic, diagnostic, or biomarker relevance)
06

Interacting drugs

None (no drugs known to interact; research and drug development focus on protein-coding genes like PARK7/DJ-1)
07

Biomarkers

None (not used as a disease or drug-response biomarker)

Beyond the preview

Go deeper on PARK7 pseudogene 2 (PARK7P2).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on PARK7 pseudogene 2 (PARK7P2).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call